CytoSorbents Corporation (CTSO)

[clints]

CytoSorbents Targets 4Q Profitability, US Trial Begun -- Market Talk
10:33 am ET November 14, 2018 (Dow Jones) Print

1533 GMT - CytoSorbents Corporation expects to pass two major milestones this year in its bid to expand the market for its blood filter to reduce chronic inflammation, the Nasdaq-listed company said at the Jefferies Healthcare conference in London Wednesday. New Jersey, U.S.-based CytoSorbents is targeting operating profitability in 4Q 2018, Chief Executive Phillip Chan told Dow Jones Newswires in an interview. He also said the company has just begun a trial to secure U.S. approval for its CytoSorb filter and hopes to receive it in 2021. "We're just getting started but I think it's going in a good way," he said. CytoSorb is already distributed in 53 countries including those in the EU. ([e-mail])

(END) Dow Jones Newswires

November 14, 2018 10:33 ET (15:33 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.